摘要
肺动脉高压(PAH)是一种肺动脉压力异常升高、伴或不伴有小肺动脉病变的恶性肺血管疾病,具有潜在的致死性。随着对PAH发病机理的深入研究,涌现出多种不同作用机制的PAH治疗药物。本文总结了近年PAH治疗药物的临床应用情况和市场现状,并阐述了其在国内的发展机遇和挑战。
Pulmonary arterial hypertension （PAH） is a malignant pulmonary vascular disease,characterized by abnormal increase in pulmonary artery pressure and accompanied by small pulmonary lesions or not,which is potentially fatal.With the in-depth study of PAH pathogenesis,PAH drugs with different mechanisms of action appear constantly.In this paper,we summarized the recent clinical application and market status of PAH drugs,and described the development opportunities and challenges in our country.
出处
《中国新药杂志》
CAS
CSCD
北大核心
2017年第19期2245-2250,共6页
Chinese Journal of New Drugs
关键词
肺动脉高压
临床用药
市场现状
pulmonary arterial hypertension
clinical application
market status
